Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy

Area of Science:

• Epigenetics and molecular biology
• Cancer genomics and therapeutics

Background:

• SWI/SNF (switch/sucrose non-fermentable) complexes are essential epigenetic regulators of gene transcription.
• Mutations in SWI/SNF-encoding genes occur in 20-25% of human cancers, often driving oncogenic processes.
• SWI/SNF-mutant cancers exhibit hypersensitivity to specific pathway perturbations, leading to synthetic lethal interactions.

Purpose of the Study:

• To review the role of SWI/SNF chromatin remodellers in gene regulation and cancer development.
• To discuss mechanisms of SWI/SNF assembly defects in oncogenesis.
• To highlight emerging targeted therapy strategies for SWI/SNF-deficient cancers.

Main Methods:

• Review of functional genomic studies and literature on SWI/SNF complexes.
• Analysis of cancer mutation prevalence and oncogenic roles of SWI/SNF.
• Exploration of synthetic lethality principles and therapeutic vulnerabilities.

Main Results:

• SWI/SNF complexes are fundamental epigenetic regulators with high mutation rates in human cancers.
• Cancer-associated SWI/SNF defects create vulnerabilities exploitable for targeted therapies.
• Synthetic lethality is a key concept for developing novel anticancer treatments.

Conclusions:

• Targeting SWI/SNF-deficient cancers via synthetic lethality is a promising therapeutic avenue.
• Emerging strategies include chemical probes and proteolysis targeting chimeras (PROTACs).
• Understanding SWI/SNF biology is critical for advancing cancer treatment.